lating factor 1 receptor (Yarden et al, 1987; Qui et al, 1987) . The ligand for c-Kit product has been cloned and variously designated as stem cell factor (SCF) (Besmer et al, 1986) , mast cell growth factor, kit ligand or steel factor Copeland et al, 1990; Nocka et al, 1990) . SCF-Kit interaction is essential for the development of melanocytes, germ cells and mast cells (Galli et al, 1993) .
Beyond a c-Kit role in cellular proliferation and differentiation (Torihashi et al, 1999) , c-Kit is involved in protecting cells from apoptosis (Ricotti et al, 1998) as demonstrated in neuroblastoma (Timeus et al, 1997) .
Recently, a role of KIT mutations and c-Kit/SCF mRNA overexpression in the development of sarcomas has been suggested (Ricotti et al, 1998; Hirota et al, 1998) . A constitutively activated mutated c-Kit protein has been demonstrated in 5 out of 49 gastrointestinal stromal tumours (GISTs) currently regarded to originate from the putative intestinal cell of Cajal on the basis of immunophenotypic Kindblom et al, 1998) and ultrastructural features (Kindblom et al, 1998) . Subsequently, an identical somatic and germ-line c-Kit mutation was found in a patient and in her nephew both suffering from multiple GISTs and, more recently, in a mother and her natural daughter (Hirota et al, 2000) . At present, after the seminal Hirota's report, there is no consensus on the frequency of c-Kit gene mutations in sporadic GISTs, ranging from 21 % (Moskaluk et al, 1999) to more than 50% (Lasota et al, 1999) although the expanded observations share the evidence of a high correlation between malignancy and c-Kit mutation. Nevertheless, virtually all GISTs with and without mutations, showed CD 117 immunoreactivity (Moskaluk et al, 1999 , Lasota et al, 1999 . Furthermore, the mRNA co-expression of c-Kit-SCF, possibly related to an autocrine loop able to protect the cells from apoptosis, has been described in six cell lines derived from pPNET (Ricotti et al, 1998 ).
Here we report the expression of the c-Kit gene and its ligand SCF, complemented by the c-Met/HGF gene system expression and c-Kit/c-Met immunophenotype in a series of synovial sarcomas (SS) already known to carry the non-random t(X;18) and over-expressing the protein encoded by the master inhibitory gene bcl2 (Mancuso et al, 2000) .
MATERIALS AND METHODS

Tumours and patients
A total of 23 synovial sarcomas from 20 patients were analysed in this study. There were 11 primary tumours, 2 local tumour relapses and 10 pulmonary metastases: 9 to the lung and 1 to the adrenal gland. Cases 19 and 20 had both primary tumour (19a, 20a) and metastasis (19b, 20b and 20c) . Anatomical location of primary tumours is detailed in Table 1 .
Morphologically, 10 cases were biphasic and 13 monophasic in sub-type. A total of 12 cases showed the fusion transcript SYT-SSX1, 10 cases the SYT-SSX2 transcript and 1 the SYT-SSX4 one. All the SS cases in the study but 4 (case nos 7, 9, 20a and 20c) have been previously reported (Mancuso et al, 2000) .
Cell lines
The human megakaryoblastic leukaemia M07e cell line was kindly provided by Prof. L Pegoraro and was kept in culture as described by Brizzi et al, JBC 1994 (Brizzi et al, 1994 . It was used as positive control for c-Kit and SCF expression.
FL-EBV cell line, derived from the fetal liver of a health donor immortalized with Epstein-Barr Virus, kindly provided by Dr Domenico Delia, was used as positive control for c-Met and HGF genes expression and was maintained in culture with 15% FCS RPMI in standard conditions.
RNA extraction and reverse transcriptase polymerase reaction (RT-PCR)
Total RNA was extracted using the RNAzol method (Gibco BRL, Life Technology) from snap-frozen tumour tissue samples stored at -80˚C. 1 µg of RNA was reverse-transcribed into cDNA using oligo (dT) primers and reverse transcriptase (Superscript II Gibco BRL, Paisley, UK) according to the manufacturer's recommendations. The integrity of cDNA was detected by the amplification of the housekeeping β-actin gene (Adams et al, 1995) . One µl of cDNA was used as template for each PCR reaction.
SYT-SSX PCR
The detection of the putative SYT-SSX1 and SYT-SSX2 was carried out with the following primers:
PCR conditions were: 35 cycles of denaturation at 94˚C for 30 s, annealing at 58˚C for 1 min and elongation at 72˚C for 1 min (Kawai et al, 1998) .
The detection of fusion transcript SYT-SSX4 was performed by a nested PCR with the following primer pairs: ICC = immunocytochemical analysis; P = primary tumour; R = local tumour ; PM = pulmonary metastasis; AM = adrenal gland metastasis; L = long form of SCF; S = short form of SCF; NE = no valuable; samples marked with an asterisk are from pre-treated patients.
SYT external 5′-CAACAGCAAGATGCATACCA-3′ SSX′′ 5′-TGCTATGCACCTGATGACGA-3′
The annealing temperature was 52˚C for 1 min.
SYT internal 5′-AGACCAACACAGCCTGGACCA-3′ SSX4′′ 5′-GGCACAGCTGTTTCCCATCA-3′
The annealing temperature was 58˚C for 1 min.
The amplification products of all the translocation breakpoints were analysed on 2% agarose gel in TAE1X buffer.
One of each fusion type transcript (SYT-SSX1, SYT-SSX2 and SYT-SSX4) was sequenced and used as positive control.
c-Kit and SCF PCR
The c-Kit mRNA expression was evaluated using the primers (Ricotti et al, 1998) 5′ forward GAGTTGGCCCTAGAAGTTAGA 5′ reverse CCTGGAGGTGGATGCAAGTT at the following conditions: 40 cycles at 94˚C for 1 min., 64˚C for 45 s, 72˚C for 1 min.
For its ligand, SCF, the amplification was carried out with the following primers 5′ forward ATTCAAGAGCCCAGAACCCA 5′ reverse CTGTTAACCAGCCAATGTACG The PCR conditions were: 40 cycles at 94˚C for 1 min., 63˚C for 45 s, 72˚C for 1 min. The use of AmpliTaq Gold was recommended.
c-Met and HGF PCR
c-Met receptor was amplified using the following primers (Moryama et al, 1995) :
The used conditions were: 5 cycles 94˚C 1 min, 58˚C 2 min, 72˚C 2 min, 30 cycles 94˚C for 30 s, 59˚C for 1 min, 72˚C for 1 min. The ligand HGF, was amplified using the primers 5′ forward GGGAAATGAGAAATGCAGCCAG 5′ reverse AGTTGTATTGGTGGGTGCTTC with the same conditions of c Met, using AmpliTaq Gold instead.
Protein extraction
Proteins were extracted from tissue samples stored at -80˚C, by homogenization at 4˚C in lysis buffer (50 mM Tris-HCl pH 7.5, 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40) supplemented with protease inhibitors. Lysis was performed by frequent vortexing, followed by sonication step. Protein lysates were then cleared by centrifugation at 14 000 rpm at 4˚C for 30 min and quantitated through BCA analysis (Pierce, Rockford, USA).
Immunoprecipitations and Western blotting
Equal amounts of lysates were subjected to immunoprecipitation by incubating with 3 µl of mouse monoclonal antibody Ab-3 (K45) (NeoMarkers, Union City, CA), directed against the c-Kit receptor, even if it was conjugated to its receptor (SCF). The M07e cell line lysate, with overexpressed c-Kit receptor, was used as positive control while the lysate from normal human synovia was used as the negative one. After a 2 h incubation with the specific antibody, at 4˚C and under gentle agitation, the protein complexes were incubated for 1 h with protein A Sepharose (Sigma, St. Louis, USA) at 4˚C with gentle agitation. Immunoprecipitates were then collected by centrifugation and washed three times with the same buffer supplemented with antiproteases. Next, the immunoprecipitated material was boiled for 5 min in Laemli buffer (62 mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 0.003% bromophenole blue) and analysed by SDS-PAGE electrophoresis under reducing conditions on a 10% acrylamide minigel (Biorad, Richmond, CA). Coloured Rainbow protein markers (Amersham, UK) were used.
Proteins were transferred to a polyvinyldene difluoride membrane and subjected to Western blotting. The membrane was saturated with 4% BSA (Amersham) for 2 h at room temperature. c-Kit protein was detected with a rabbit polyclonal antibody (C-19, Santa Cruz Biotecnology, CA, USA) diluted 1:200 in TBS (20 mM Tris-HCl pH 7.5, 154 mM NaCl). The secondary antibody was used at the recommended dilution (Sigma). Specific bands corresponding to the investigated proteins were detected using a chemioluminescent technique, according to the manufacturer's recommendations (ECL detection system, Amersham).
Immunoprecipitation experiments against the β-actin protein were performed as previously described using 1 µl of the specific polyclonal antibody (Sigma) and using all the unbound total proteins derived form the c-Kit immunoprecipitation experiments. The subsequent Western blot was incubated with a mouse monoclonal β-Actin antibody (Sigma) diluted 1:5000.
Immunocytochemical (ICC) analysis
ICC study was performed by the streptavidine-peroxidase conjugated method (Shi et al, 1998) . The following primary antibodies were applied: anti c-Kit polyclonal rabbit antibody (C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti c-Met polyclonal rabbit antibody (C-12, Santa Cruz Biotechnology, Santa Cruz, CA, USA), the monoclonal Bcl2 antibody (mouse clone 124, kindly donated by Dr Mason, Department of Histopathology, London University College) to paraffin-embedded sections using 1:100 and 1:50 dilutions, and 1:20 respectively.
The specificity of the primary antibodies c-Met and c-Kit were confirmed by the use of specific peptides (sc-168 P, Santa Cruz, for c-Kit and sc-10 P, Santa Cruz, for c-Met). Competition experiments were performed as follow: diluted antibody (1:50) was preincubated with 4 µg of the specific peptide and incubated at 37˚C for 2 h and then utilized at the working dilution following standard procedures.
Cytokeratin positivity was detected using a pool of antibody constituted by 34 βE12 (Dako) and KS 8.12 (Sigma) diluted 1:200, following standard procedures.
RESULTS
Since, according to a recent report (Zhang et al, 1998) human mast cells can be a cellular source of SCF, and SS is known to bear in some cases a relevant number of this type of cell (Ueda et al, 1988) , an evaluation of this cellular component has been performed. A relevant number of mast-cells was observed within the spindle cell component in some areas of surgical material sections in six cases (three biphasic and three monophasic) of SSs (case nos 3, 10, 13, 14, 16 and 20b of Table 1 ). However, none of the control sections of cryopreserved material showed a significant mast-cell component.
SCF and c-Kit RNA expression
The mRNA of the c-Kit gene was detected in all the analysed samples but case nos 14, 19a and 20b of Table 1 ( Figure 1A ) and this expression profile parallels well with SCF mRNA expression. On a total of 20 positive cases, 14 tumours showed the specific SCF bands (494 bp and 409 bp, named L and S respectively) and 6 tumours (n. 5, 7, 8, 12, 19b and 20a) showed only the higher SCF band (L) ( Figure 1B) . The positive control M07e cell line displayed mRNA for both c-Kit receptor and its ligand represented by the two specific bands.
c-Kit Immunoistochemical analysis
The immunostaining intensity was faint, diffuse and cytoplasmic in the spindle cells of monophasic SSs. In biphasic tumours a definite enhancement of reactivity was observed in the epithelial component which paralleled the switch off of the immunoreactivity of the spindle cells intermixed with or surrounded the epithelial nests/structures in most of the cases (Figures 2A and  2B) .
Such an immunoreactivity was inhibited by the pre-incubation of the antibody with a specific synthetic peptide against which the antibody was raised.
Cytokeratin positivity, like c-Kit staining, was restricted to the epithelial cells ( Figures 2E and 2F) .
Immunoprecipitation of c-Kit receptor
Three cases where a large amount of frozen material was available, were chosen for immunoprecipitation experiments.
A band of 150 kDa, comigrating with the positive control of the c-Kit of M07e cell line, was detected in two biphasic synovial sarcomas (case nos 7 and 20a of Table 1) but not in one monophasic synovial sarcoma (case no. 11 of Table 1 ) and in the normal human synovia (Figure 3) . As control, the bound proteic material derived form c-Kit IP was secondly immunoprecipitated with a specific antibody for β-Actin protein. The intensity of the detected band (50KDa) was identical in all the analysed cases (Figure 3) . These results correlated to the ICC data even if case 11 showed both a c-Kit mRNA expression and reactivity with immunistochemical analysis.
HGF and c-Met RNA expression
All cases were tested for the presence of HGF mRNA. Fourteen tumours showed the presence of the expected band and nine cases resulted negative (case nos 6, 7, 12, 14, 15, 19a, 19b, 20a and 20b of Table 1) ( Figure 1D ).
c-Met mRNA receptor was found in all tumours but cases 14, 19a and 20b ( Figure 1C) .
In six cases (6, 7, 12, 15, 19b and 20a) only the presence of c Met RNA, not associated to the presence of its ligand, HGF mRNA, was detected.
c-Met immunoistochemical analysis
All the analysed tumours were positive but case nos 5 and 8 even if a mRNA expression was detected for both c-Met gene and its ligand. Two cases were not assessable cases (16 and 19b) .
The areas overexpressing c-Met corresponded to the epithelial component of biphasic SSs, however a faint reactivity was present in the spindle cell component of both biphasic and monophasic tumours in accordance with previous reports (Kuhnen et al, 1998) .
mRNA expression data (RT-PCR) (Table 1) did not show any correlation with pathologic stage (primary vs metastasis), histologic sub-type, fusion transcript and anatomical localization.
DISCUSSION
In this study, 23 cases of primary and metastatic synovial sarcomas, 10 biphasic and 13 monophasic in sub-type, were analysed. We investigated the expression of c-Kit and its ligand, SCF, in addition to c-Met tyrosine kinase receptors and its ligand, HGF, by analysing the presence of related mRNAs. Western blot and immunocytochemical analysis were also performed thus confirming at protein level the expression of the two receptors.
To our knowledge, the present report is the first study that underlines the presence of the c-Kit/SCF system in SSs. Immunocytochemical analysis showed that the overexpression of this receptor is mainly restricted to the epithelial component of biphasic SSs. Accordingly, the band detected by immunoprecipitations and Western blot, corresponding to the c-Kit receptor, was only found in the proteic lysate obtained from two biphasic tumours and not in the monophasic one. The weak c-Kit expression observed in the monophasic subtype was probably insufficient to be detected by this technique. Unfortunately, due to the delayed snap-freezing of the tumour material, we were unable to assess the phosphorylation status of the receptor. Comparing the presence of RT-PCR analysis. RNA was reverse transcribed and the obtained cDNA was subjected to specific PCR. PCR products were run in a 1.8% agarose gel and photographed under UV light. Lane 1s to 14 correspond to case nos 1, 2, 3, 4, 5, 6, 7, 8, 11, 13, 14, 19a, 20a and 20c of both c-Kit and SCF mRNA we always observed a correlation between them: their tight association suggests therefore the existence of a possible autocrine loop in this type of tumour and we could thus hypothesize that the latter express a wild-type receptor.
On the contrary, in the GISTs model, the constitutive phosporylation of the c-Kit receptor is due to point mutations in the exon 11 , and makes redundant the production of the ligand, SCF, whose expression was always detected in our tumours. In most of our cases, we identified two SCF isoforms, here defined L and S. The S isoform, lacking exon 6, encodes a membrane-bound SCF while isoform L encodes a protein containing a cleavage site that makes the ligand susceptible to post-translational proteolysis, yielding a soluble SCF. Both isoforms are biologically active Toskoz et al, 1992) but the mechanisms that control the tissue-specific and developmentally regulated production of SCF L vs SCF S are not well understood. In our SS series, we never detected the S isoform alone but we found the co-presence of the two isoforms L and S or the L form alone. The expression of c-Kit and of its ligand SCF, both as L or S form, did not show any segregation either to the pathologic tumour stage, histologic sub-type, fusion transcript, or anatomical localization. The possibility that the SCF mRNA transcripts in our cases were not derived from tumour cells but from contaminating mast cells (Ueda et al, 1988) was ruled out by the microscopic control on frozen sections of cryopreserved samples before molecular analysis. The presence of c-Kit oncogene and its ligand, SCF, was recently reported in pPNETs (Ricotti et al, 1998 ). This finding is not unexpected since we know that undifferentiated SS may share some morphologic and immunophenotypic characteristics with pPNETs (Dei Tos et al, 1995; Folpe et al, 1998; van de Rijn et al, 1999) and that, though rarely, SSs may show pPNET featuring components (Mezzelani et al, 1998; Noguera et al, 1998) .
A concomitant mRNA expression of HGF and c-Met genes was firstly reported in cell lines derived from other tumours of mesenchymal origin, such as a human glioma (Moryama et al, 1995) and human osteosarcoma cell lines (Cooper et al, 1984) . More recently, c-Met protein expression was reported in two different series of SSs (Motoi et al, 1998; Kuhnen et al, 1998) . In order to complement our c-Kit data, we investigated the expression of c-Met and its ligand, HGF, along with c-Met protein.
Although our molecular results did not completely fit in with the immunocytochemical ones and some discrepancies need further investigation, immunophenotyping results were superimposable to those already described by Kuhnen and colleagues. We detected in fact, a strong expression of c-Met gene product in the epithelial component and a faint reactivity in the spindle cell one. Since it is currently conceived that each SS epithelial and spindle tumour cell harbours the same type of translocation t(X;18) (Clark et al, 1994) , the evidence that the two TK related genes, c-Met and c-Kit, even though more expressed in the biphasic SS are also expressed in monophasic subtype, gives further support to the hypothesis that the two SS subtypes may truly represent a 'carcinosarcoma' with differently developed epithelial component (Leader et al, 1987; Miettinen et al, 1984) .
Cumulatively, the current evidence suggests that the non-random SS translocation t(X;18) may trigger the transactivation of a cascade of genes such as c-Met, c-Kit, and their ligands, yielding two different autocrine loops: the first acting on the epithelial differentiation and the second working in a program protecting from apoptosis (Timeus et al, 1997) . Since in a previous study (Mancuso et al, 2000) we have shown that a Bcl2 over-expression is a part of the SS gene profile and this expression, at variance with c-Kit receptor, is mainly restricted to the spindle cell component, the scenario that can be envisaged might be as follows. The epithelial differentiation process is driven by the c-Met gene and this driving parallels the shifting of the antiapoptotic role from Bcl2 to the c-Kit gene during transition from the spindle uncommitted to the epithelial differentiated cells. The shifting is in keeping with the tight correlation between the cell type and both modulation of expression and specific localization of the c-Kit gene product we observed. In fact, in biphasic SS the faint decoration of the spindle cells tends to disappear in the spindle, albeit Bcl2 positive, cells, surrounding the epithelial areas to which the strongest c-Kit immunoreactivity is restricted (Figure 2A-C) and the cytokeratin positivity confirm this shifting ( Figure 2E ). Moreover, primary biphasic tumours may reoccur as monophasic SSs (Mancuso et al, 2000) . Again this does not appear a contradictory finding since the modulations and changes of morphologic features that occur and that we observed during recurrences or metastatic progression, may be ascribed to the dynamic plasticity of the expression of the involved genes. Table 1 ; lane 3: monophasic tumour case n. 11 of Table 1 ) and lane 4: from normal tissue (synovia). All the samples were secondly immunoprecipitated with anti β-actin antibody. All lanes were reacted with ECL detection reagents according to manufacturer instructions
